Abstract
Diabetes mellitus is a chronic metabolic disease affected a wide range of population all over the world and leads to development of many severe long term complications. Aldose reductase (AR) is the enzyme considered to play a key role in the development of secondary diabetic complications via polyol pathway. AR inhibition has been proposed as a strategy to prevent and delayed such complications. 2,4-thiazolidinedione derivatives being isosteres of hydantoin, emerged as potential AR inhibitors with antidiabetic activity. Therefore, we have designed novel arylidene-2, 4-thiazolidinediones as AR inhibitors using molecular docking technique. Mol-dock score along with re-rank score was the criteria for measuring the affinity of STMG-(1-40) with the AR enzymes. Result of present study will provide a new guideline for the further design of novel potent inhibitors of AR in the management of diabetes along with its complications.
Keywords: Diabetic complications, Diabetes, Docking, Aldose reductase, Nephropathy, Thiazolidinedione.
Letters in Drug Design & Discovery
Title:Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Volume: 10 Issue: 7
Author(s): Manoj Kumar Gautam and Suresh Thareja
Affiliation:
Keywords: Diabetic complications, Diabetes, Docking, Aldose reductase, Nephropathy, Thiazolidinedione.
Abstract: Diabetes mellitus is a chronic metabolic disease affected a wide range of population all over the world and leads to development of many severe long term complications. Aldose reductase (AR) is the enzyme considered to play a key role in the development of secondary diabetic complications via polyol pathway. AR inhibition has been proposed as a strategy to prevent and delayed such complications. 2,4-thiazolidinedione derivatives being isosteres of hydantoin, emerged as potential AR inhibitors with antidiabetic activity. Therefore, we have designed novel arylidene-2, 4-thiazolidinediones as AR inhibitors using molecular docking technique. Mol-dock score along with re-rank score was the criteria for measuring the affinity of STMG-(1-40) with the AR enzymes. Result of present study will provide a new guideline for the further design of novel potent inhibitors of AR in the management of diabetes along with its complications.
Export Options
About this article
Cite this article as:
Gautam Kumar Manoj and Thareja Suresh, Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors, Letters in Drug Design & Discovery 2013; 10 (7) . https://dx.doi.org/10.2174/1570180811310070007
DOI https://dx.doi.org/10.2174/1570180811310070007 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Current Diabetes Reviews Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Controlling the Flow of Energy: Inhibition and Stimulation of the Creatine Transporter
Current Enzyme Inhibition Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Meet Our Section Editor
Current Diabetes Reviews Contribution of Analytical Microscopies to Human Neurodegenerative Diseases Research (PSP and AD)
Mini-Reviews in Medicinal Chemistry The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Role of PGC-1α in the Pathogenesis of Neurodegenerative Disorders
Current Drug Targets Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews The Complex Biology of FOXO
Current Drug Targets Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry